title: Convection-enhanced delivery of therapeutics for brain disease, and its optimization.
abstract: Convection-enhanced delivery (CED) is the continuous injection under positive pressure of a fluid containing a therapeutic agent. This technique was proposed and introduced by researchers from the US National Institutes of Health (NIH) by the early 1990s to deliver drugs that would otherwise not cross the blood-brain barrier into the parenchyma and that would be too large to diffuse effectively over the required distances were they simply deposited into the tissue. Despite the many years that have elapsed, this technique remains experimental because of both the absence of approved drugs for intraparenchymal delivery and the difficulty of guaranteed delivery to delineated regions of the brain. During the first decade after the NIH researchers founded this analytical model of drug distribution, the results of several computer simulations that had been conducted according to more realistic assumptions were also published, revealing encouraging results. In the late 1990s, one of the authors of the present paper proposed the development of a computer model that would predict the distribution specific to a particular patient (brain) based on obtainable data from radiological images. Several key developments in imaging technology and, in particular, the relationships between image-obtained quantities and other parameters that enter models of the CED process have been required to implement this model. Note that delivery devices need further development. In the present paper we review key features of CED as well as modeling of the procedure and indulge in informed speculation on optimizing the direct delivery of therapeutic agents into brain tissue.
authors.affiliation: Therataxis, LLC, Baltimore, Maryland 21210-2415, USA. raghu@therataxis.com
authors.forename: Raghu
authors.initials: R
authors.lastname: Raghavan
authors.forename: Martin L
authors.initials: ML
authors.lastname: Brady
authors.forename: María Inmaculada
authors.initials: MI
authors.lastname: Rodríguez-Ponce
authors.forename: Andreas
authors.initials: A
authors.lastname: Hartlep
authors.forename: Christoph
authors.initials: C
authors.lastname: Pedain
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000503:physiopathology / Q000601:surgery*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004058:Diffusion; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods / Q000639:trends*; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000009:adverse effects / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents